Start4507 • TYO
add
Shionogi & Co Ltd
Seneste lukkekurs
2.059,00 ¥
Dagsinterval
2.062,50 ¥ - 2.109,50 ¥
Årsinterval
1.944,66 ¥ - 2.712,33 ¥
Markedsværdi
1,86 bio. JPY
Gns. volumen
2,61 mio.
P/E-værdi
11,59
Udbytteprocent
2,71 %
Primær børs
TYO
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 116,38 mia. | -4,00 % |
Driftsudgifter | 52,93 mia. | -3,66 % |
Nettoindtægt | 52,50 mia. | 9,30 % |
Overskudsgrad | 45,11 | 13,86 % |
Earnings per share | — | — |
EBITDA | 53,13 mia. | -5,14 % |
Effektiv afgiftssats | 8,28 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 303,40 mia. | 20,22 % |
Samlede aktiver | 1,46 bio. | 3,34 % |
Samlede passiver | 145,93 mia. | -18,09 % |
Samlet egenkapital | 1,31 bio. | — |
Shares outstanding | 850,69 mio. | — |
Kurs/indre værdi | 1,23 | — |
Afkast af aktiver | 8,22 % | — |
Afkast af kapital | 9,10 % | — |
Pengestrøm
Nettoændring i likviditet
(JPY) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 52,50 mia. | 9,30 % |
Pengestrøm fra drift | 45,30 mia. | 220,14 % |
Pengestrøm fra investering | -17,63 mia. | 47,30 % |
Pengestrøm fra finansiering | -1,11 mia. | 94,50 % |
Nettoændring i likviditet | 21,45 mia. | 158,43 % |
Fri pengestrøm | 8,02 mia. | 135,46 % |
Om
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Administrerende direktør
Grundlagt
1878
Hovedkvarter
Website
Ansatte
4.959